Immutep Limited ADR(IMMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.28 | Insider Own | 0.84% | Shs Outstand | 7.4M | Perf Week | -4.38% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 14.31% | Insider Trans | - | Shs Float | 7.3M | Perf Month | -32.6% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -1.45 | Inst Own | 1.13% | Short Float | 0.46% | Perf Quarter | -59.78% |
| Income | -0.05B | P/S | 2.25 | EPS this Y | 75.42% | Inst Trans | - | Short Ratio | 2.09 | Perf Half Y | -64.92% |
| Sales | 0.01B | P/B | 0.53 | EPS next 5Y | 41.66% | ROA | -66.76% | Short Interest | 0.03M | Perf YTD | -94.65% |
| Book/sh | 5.79 | P/C | 0.47 | EPS past 3/5Y | -7.01% 0.02% | ROE | -78.38% | 52W High | -95.67% ($70.60) | Perf Year | -92.03% |
| Cash/sh | 6.47 | P/FCF | - | Sales past 3/5Y | - | ROIC | -124.19% | 52W Low | 0.66% ($3.04) | Perf 3Y | -91.64% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -33.93% | Gross Margin | 85.21% | Volatility(W/M) | 9.49% 7.14% | Perf 5Y | -96.43% |
| Dividend TTM | - | EV/Sales | -2.44 | Sales Y/Y TTM | - | Oper. Margin | -586.33% | ATR (14) | 0.29 | Perf 10Y | -94.6% |
| Dividend Ex-Date | - | Quick Ratio | 5.69 | EPS Q/Q | 3.43% | Profit Margin | -534.13% | RSI (14) | 24.09 | Recom | 1.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.69 | Sales Q/Q | - | SMA20 | -11.57% ($3.46) | Beta | 2.28 | Target Price | $19.66 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/30 | SMA50 | -41.78% ($5.26) | Rel Volume | 0.66 | Prev Close | $3.33 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -548.84% -15.17% | SMA200 | -82.1% ($17.09) | Avg Volume(3M) | 0.02M | Price | $3.06 |
| IPO | 2012/4/17 | Option/Short | No/Yes | Trades | 155 | Volume | 10,594 | Change | -8.11% |
🧬 A global biotech company pioneering in the LAG-3 immunotherapy field, which is a key target for immune checkpoint inhibitors. Through its proprietary soluble LAG-3 protein technology, the company is offering more effective and safer next-generation immunotherapy alternatives for patients with cancer and autoimmune diseases.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
IMMP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +75.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $225. Peers typically go for $1,010.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #462 of 597 in the industry
Based on market cap of $23M.
CVM#460 Cel-Sci Corp $24M PER - 
CRVO#461 CervoMed Inc $24M PER - IMMP#462 Immutep Limited ADR $23M PER - 
ATOS#463 Atossa Therapeutics Inc $22M PER - 
IGC#464 IGC Pharma Inc $21M PER - 
FAQ
What kind of company is IMMP?
IMMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMMP?
The market cap of IMMP is approximately $23M, ranking 5,168 within its sector.
What is the 52-week high and low for IMMP?
IMMP has recorded a 52-week high of $70.60 and a low of $3.04.
